Form 4: Ocular Therapeutix CFO Sells Shares for Tax Obligations

Ocular Therapeutix's CFO and COO, Donald Notman, sold 1,066 shares of common stock at a weighted average price of $12.43 to cover tax obligations related to RSU vesting.

Summary

• Donald Notman, Chief Financial Officer and Chief Operating Officer of Ocular Therapeutix, Inc., reported a sale of 1,066 shares of common stock.
• The shares were sold on September 2, 2025, at a weighted average price of $12.43 per share, with individual transaction prices ranging from $12.29 to $12.5622.
• This sale was executed pursuant to a durable automatic sales instruction letter dated May 13, 2022, which is a Rule 10b5-1(c) plan, to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 29, 2025.
• The sale does not represent a discretionary trade by Donald Notman.
• Following this transaction, Donald Notman beneficially owns 308,807 shares of common stock.
• The reported beneficial ownership includes 1,429 shares of common stock acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2025.

Sentiment

Score: 5

Explanation: The transaction is a non-discretionary sale to cover tax obligations from RSU vesting, which is a routine event for executives. The simultaneous acquisition of shares through an ESPP further balances the sentiment, indicating no strong positive or negative signal regarding the company's prospects.

Positives

• The sale of shares was non-discretionary and pre-planned under a Rule 10b5-1(c) plan, indicating it was a routine event for tax purposes rather than a signal of negative insider sentiment.
• Donald Notman acquired 1,429 shares through the Employee Stock Purchase Plan, demonstrating continued participation in employee stock ownership programs.

Negatives

• The transaction represents a reduction in direct beneficial ownership by a key executive, albeit for tax-related purposes.

Future Outlook

No specific forward-looking statements or guidance are provided in this filing, as it primarily reports an insider transaction.

Management Comments

• The sales do not represent a discretionary trade by the reporting person.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information directly related to broader industry trends or competitive landscape.

Corporate Governance

Related Party Transactions

• Acquisition of 1,429 shares of common stock under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2025.
• Vesting of restricted stock units on August 29, 2025, leading to tax withholding obligations that were satisfied by the reported share sale.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but its non-discretionary nature for tax purposes suggests no change in management's confidence in the company.
• Employees: The acquisition of shares through the Employee Stock Purchase Plan highlights the company's ongoing employee stock ownership programs.

Key Dates

Recommendation

This Form 4 details a non-discretionary sale by a key executive to cover tax obligations from RSU vesting, which is a routine event and does not signal a change in management's outlook. The simultaneous acquisition of shares through an Employee Stock Purchase Plan further indicates a neutral stance. Therefore, the filing itself does not provide new information warranting a change in investment recommendation, suggesting a 'hold' position.

Keywords

OCULAR THERAPEUTIX, OCUL, Form 4, insider trading, stock sale, RSU vesting, tax withholding, Donald Notman, CFO, COO, 10b5-1 plan, employee stock purchase plan